A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
Status: | Active, not recruiting |
---|---|
Conditions: | Hepatitis, Hepatitis |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 3 - 17 |
Updated: | 3/15/2019 |
Start Date: | June 16, 2014 |
End Date: | February 6, 2020 |
A Phase IIIb, Randomized, Open-Label Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Patients in Children With HBeAg Positive Chronic Hepatitis B in the Immune-Tolerant Phase
This randomized, controlled, parallel group, open-label multicenter study will evaluate the
efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus
lamivudine or entecavir compared with an untreated control group in participants with HBeAg
positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED
efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus
lamivudine or entecavir compared with an untreated control group in participants with HBeAg
positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED
Inclusion Criteria:
- Positive for HBsAg and HBeAg for more than 6 months prior to baseline
- Detectable HBV-DNA (>20,000 IU/mL) as measured by polymerization chain reaction (PCR)
or hybridization on at least 2 occasions at least one month apart with the latest
determination obtained less than or equal to (
- Compensated liver disease (Child-Pugh Class A clinical classification)
- Either Liver biopsy performed within 2 years prior to baseline showing no or minimal
fibrosis (Liver Biopsy Scores and stable normal ALT levels (less than or equal to
upper limit of normal [ULN]) during the 6 months leading up to baseline (including two
separate occasions at least 1 month apart over the 6 months prior to baseline).
Screening ALT levels must be normal ( during the 1 year leading up to baseline (including three separate occasions at least
1 month apart over the 1 year prior to baseline) and no signs of hepatocellular
carcinoma (HCC), advanced fibrosis/cirrhosis, or splenomegaly on liver abdominal
ultrasound at screening. Screening ALT levels must be normal (
Exclusion Criteria:
- Participants who have received investigational drugs or licensed treatments with anti
HBV activity (Exception: Participants who have had a limited [ acyclovir for herpetic lesions more than 1 month before the study baseline visit are
not excluded)
- Participants who have participated in any other clinical trial or who have received
any investigational drug within 6 months prior to baseline
- Known hypersensitivity to interferon (IFN), pegylated interferon-alfa-2a or lamivudine
or entecavir
- Positive test results at screening for hepatitis A virus Immunoglobulin M (IgM)
antibody (Ab), anti-hepatitis C virus (HCV) Ab, anti- hepatitis D (HDV) Ab or
anti-human immunodeficiency virus (HIV) Ab
- Decompensated liver disease (e.g., Child-Pugh Class B or C clinical classification or
clinical evidence such as ascites or varices)
- Advanced fibrosis or cirrhosis
- Suspicion of HCC on liver abdominal ultrasound (all patients to have liver abdominal
ultrasound within 6 months prior to baseline)
- History or other evidence of a medical condition associated with chronic liver disease
other than CHB including metabolic liver diseases such as hemochromatosis, Wilson's
disease or alpha-1 anti-trypsin deficiency
- Active substance abuse within 6 months prior to screening
- Sexually active females of childbearing potential and sexually active males who are
not willing to utilize reliable contraception during treatment and for 90 days
following the end of treatment
- Females who are pregnant or who are breastfeeding (females of childbearing potential
who have a positive urine or serum pregnancy test result within 24 hours of baseline
are excluded)
We found this trial at
4
sites
72 King William Road
North Adelaide, South Australia 5006
North Adelaide, South Australia 5006
Click here to add this to my saved trials

Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
Click here to add this to my saved trials

Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials

Click here to add this to my saved trials
